Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulised RESP30X Nitric Oxide in Non-Cystic Fibrosis Bronchiectasis (NOPA)
2023-508706-23-00Phase 2Completed
- Sponsor
- Thirty Respiratory Limited
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2 trial of RESP302 and ALX1 in bronchiectasis and Airways Infection (2 arms), sponsored by Thirty Respiratory Limited. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory parameters and 1 more. Started Apr 2024; status: completed.
02
Drugs
RESP302ALX1
03
Conditions
bronchiectasisAirways Infection
Beyond the preview
Go deeper on 2023-508706-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508706-23-00.